<DOC>
	<DOCNO>NCT02629328</DOCNO>
	<brief_summary>This study quantify safety efficacy CardioCel implant tri-leaflet repair . 80 patient 7 site Europe US treat CardioCel implant .</brief_summary>
	<brief_title>CardioCel Tri-leaflet Repair Study</brief_title>
	<detailed_description>The purpose study evaluate safety efficacy CardioCel repair aortic valve stenosis and/or insufficiency . CardioCel cardiovascular patch manufacture call ADAPT® technology . The ADAPT technology use bovine spongiform encephalopathy-free pericardium process several way make biocompatible human tissue . CardioCel provide shelf material solution tri-leaflet repair surgery due functional attribute , low propensity post implant calcification , overall biocompatibility . As result adverse event complication associate autologous pericardium repair surgery mitigate . In study patient suffer moderate-to-severe aortic stenosis and/or aortic insufficiency include . In study 80 patient enrol 7 center Europe US . The expected study duration 36 month ; 12 month recruitment 24 month follow-up . CardioCel US FDA clear repair cardiac vascular defect , include intra-cardiac defect ; septal defect , valve annulus repair , great vessel reconstruction , peripheral vascular reconstruction , suture line buttress pericardial closure .</detailed_description>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Aortic Valve Insufficiency</mesh_term>
	<criteria>1 . The subject 's annular measurement ≥ 19 mm &lt; 27mm confirmed preop echo inter commissure distance equal big 19mm confirm intraoperatively . 2 . The subject suitable trileaflet repair . 3 . The subject document moderatetosevere AS and/or AI . 4 . The subject willing able comply specify followup evaluation , include trans oesophageal echocardiography ( TEE ) inadequate image transthoracic echocardiography ( TTE ) ass aortic valve . The subject review sign write informed consent form . 5 . The subject upon final intraoperative assessment intracardiac anatomy suitable trileaflet repair use CardioCel . 1 . Greater 85 year age time consent . 2 . The subject 's annular measurement &lt; 19 mm &gt; 27mm . 3 . All patient exclude require emergent surgery ( within 24 hour presentation emergency department ) reason . 4 . The subject exclude preexist valve prosthesis aortic position . 5 . Patients require repair cardiac valve exclude . 6 . The subject active endocarditis . 7 . Heavily calcify aortic root `` porcelain aorta '' ( evidenced cardiac echo ) . 8 . Leukopenia WBC less 3000 cell per microliter . 9 . Acute anaemia haemoglobin less 8 g/dL . 10 . Platelet count le 150.000 platelets/microliter . 11 . History define bleed diathesis coagulopathy subject refuse blood transfusion . 12 . Active infection require antibiotic therapy ( temporary illness , subject may enrol 24 week discontinuation antibiotic ) . 13 . Subjects trans oesophageal echocardiography ( TEE ) contraindicate . 14 . Low Ejection Fraction ( EF ) &lt; 35 % . 15 . Life expectancy &lt; 1 year , severe comorbidities , cancer , dialysis , severe COPD investigator 's discretion 16 . The subject illicit drug user , alcohol abuser , prisoner , institutionalise , unable give inform consent . 17 . The subject pregnant lactating ( nonpregnancy confirm pregnancy test child bear potential female prior enrolment ) . 18 . Recent ( within 6 month ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . 19 . Myocardial Infarction ( MI ) within one month trial inclusion 20 . Upon intraoperative assessment intracardiac anatomy patient suitable trileaflet repair use CardioCel .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CardioCel</keyword>
	<keyword>FDA clear</keyword>
	<keyword>Tri-leaflet repair</keyword>
	<keyword>Aortic valve</keyword>
</DOC>